Cerus Corporation Provides INTERCEPT Red Blood Cell CE Mark Application Update
Regulatory Progress: Cerus Corporation announced that TÜV-SÜD has completed the review of the clinical module for the CE Mark submission of its INTERCEPT Red Blood Cells (RBCs), allowing the Czech Republic's State Institute for Drug Control to begin reviewing the active pharmaceutical ingredient module.
Clinical Trial Impact: The successful review included positive results from a U.S. Phase 3 clinical trial, which expands the CE Mark submission to cover all patient indications for RBC transfusion, while Cerus continues to work with regulatory bodies to finalize the review process.
Trade with 70% Backtested Accuracy
Analyst Views on CERS
About CERS
About the author
TG Therapeutics Reports $616 Million Revenue for FY 2025, Shares Surge 11.6%
- Strong Financial Performance: TG Therapeutics reported preliminary total global revenue of approximately $616 million for FY 2025, with Q4 U.S. net product revenue for BRIUMVI at about $182 million, indicating robust market performance that is expected to boost shareholder confidence.
- Significant Stock Surge: Following the earnings report, TG Therapeutics shares jumped 11.6% to $31.10 on Wednesday, reflecting investor optimism about the company's growth potential, which may attract more capital inflow.
- Positive Market Reaction: Despite a broader market decline with the Nasdaq Composite falling over 200 points, TG Therapeutics' strong financial data allowed it to stand out among numerous stocks, showcasing its competitiveness in the biopharmaceutical sector.
- Optimistic Future Outlook: Although the financial figures are unaudited, the preliminary results suggest that the company is poised for continued growth, particularly in the marketing of its BRIUMVI product, which could further enhance its market share.
China SXT Pharmaceuticals (SXTC) Closes $10 Million Offering, Stock Rises 17.4%
- Successful Financing: China SXT Pharmaceuticals, Inc. announced the closing of a registered direct offering valued at approximately $10 million, selling 66,666,666 Class A ordinary shares at $0.15 each to a single investor, thereby strengthening its balance sheet and boosting investor confidence.
- Financial Guidance: TG Therapeutics reported preliminary U.S. net product revenue for its multiple sclerosis therapy BRIUMVI for Q4 and full-year 2025, with shares rising 6.99% to $29.82, showcasing the company's growth potential.
- FDA Review Progress: Argenx SE's supplemental Biologics License Application for VYVGART, aimed at treating adults with acetylcholine receptor antibody seronegative generalized myasthenia gravis, has been accepted for priority review by the FDA, with a target action date of May 10, 2026, indicating potential for expanded indications.
- Market Trends: Cosmos Health Inc. saw its stock rise 6.09% to $0.4961 despite no specific news, reflecting speculative interest and momentum trading in the micro-cap healthcare sector.
Cerus (CERS) Q4 Product Revenue Expected at $57.8M, 14% YoY Growth
- Revenue Growth: Cerus anticipates Q4 product revenue to reach $57.8 million, reflecting a 14% year-over-year increase, indicating strong momentum in its blood safety products, particularly the IFC segment.
- IFC Performance: The INTERCEPT Fibrinogen Complex (IFC) is expected to contribute $4.2 million in Q4, showcasing a year-over-year growth of approximately 40%, which underscores the increasing market demand for this product and strengthens Cerus's competitive position.
- Full-Year Outlook: For FY 2025, Cerus raises its product revenue guidance to a range of $202 million to $204 million, representing a 14% increase year-over-year, with IFC expected to account for $16.7 million, reflecting an impressive 80% growth, demonstrating the company's confidence in future performance.
- 2026 Revenue Guidance: The company projects FY 2026 product revenue between $224 million and $228 million, indicating a year-over-year growth of 9%-11%, with expected IFC revenue of $20 million to $22 million, translating to a 20%-30% increase, laying a solid foundation for sustained growth ahead.
Cerus Reports 14% Increase in 2025 Product Revenue to $206.1 Million
- Significant Revenue Growth: Cerus reported a product revenue of $206.1 million for 2025, reflecting a 14% increase from 2024, indicating sustained demand in the global blood safety market and enhancing its market position.
- Expanded Patient Access: By facilitating approximately 3 million INTERCEPT treated blood component doses across 40 countries, Cerus demonstrates the widespread application of its products globally, further solidifying its leadership in the industry.
- Positive Future Outlook: Cerus anticipates multiple milestones in 2026, including continued expansion of its commercial reach and advancement of its product development pipeline, which will help improve the company's financial performance and competitive edge.
- Enhanced Financial Transparency: Cerus plans to release complete financial results for 2025 in early March 2026, boosting investor confidence in the company's financial health and increasing market interest in its stock.
Biotech Stocks Rise in After-Hours Trading Driven by Data Expectations and Momentum Buying
Biotech Market Gains: After-hours trading on Wednesday saw significant gains in small-cap and micro-cap biotech stocks, driven by a mix of upcoming clinical milestones and a general positive sentiment in the market following the Fed's rate cut.
Agape ATP Corp. Surge: Agape ATP Corp. experienced a notable 29.41% increase in after-hours trading, attributed to a broader risk-on reaction in micro-cap stocks, despite no specific news from the company.
Corbus Pharmaceuticals Update: Corbus Pharmaceuticals saw a 12.76% rise ahead of a key clinical update regarding its Phase 1a study of CRB-913, with anticipation around the upcoming data likely fueling investor interest.
Other Notable Movers: Companies like Anebulo Pharmaceuticals, Cue Biopharma, and Curis also reported gains in after-hours trading, reflecting a broader recovery in biotech sentiment, while Cerus Corporation continued its upward trend following a new purchasing agreement.
Cerus Corporation Unveils Abstracts and Hosts Industry Workshop on IFC at the 2025 AABB Annual Meeting
Cerus Corporation Workshop Announcement: Cerus Corporation will host a workshop on the benefits of INTERCEPT Fibrinogen Complex at the 2025 AABB Annual Meeting in San Diego, emphasizing their commitment to innovations in transfusion medicine.
Abstract Presentations: Eighteen Cerus-related abstracts will be presented at the AABB meeting, showcasing the impact of their technologies on blood safety and availability.
Workshop Details: The workshop, scheduled for October 27, 2025, will feature speakers from the University of California, San Diego, and OneBlood, focusing on blood center perspectives regarding INTERCEPT Fibrinogen Complex.
Company Overview: Cerus Corporation is dedicated to enhancing blood safety through its INTERCEPT Blood System, which is globally available and FDA-approved for pathogen reduction in blood components.
TG Therapeutics Reports $616 Million Revenue for FY 2025, Shares Surge 11.6%
- Strong Financial Performance: TG Therapeutics reported preliminary total global revenue of approximately $616 million for FY 2025, with Q4 U.S. net product revenue for BRIUMVI at about $182 million, indicating robust market performance that is expected to boost shareholder confidence.
- Significant Stock Surge: Following the earnings report, TG Therapeutics shares jumped 11.6% to $31.10 on Wednesday, reflecting investor optimism about the company's growth potential, which may attract more capital inflow.
- Positive Market Reaction: Despite a broader market decline with the Nasdaq Composite falling over 200 points, TG Therapeutics' strong financial data allowed it to stand out among numerous stocks, showcasing its competitiveness in the biopharmaceutical sector.
- Optimistic Future Outlook: Although the financial figures are unaudited, the preliminary results suggest that the company is poised for continued growth, particularly in the marketing of its BRIUMVI product, which could further enhance its market share.
China SXT Pharmaceuticals (SXTC) Closes $10 Million Offering, Stock Rises 17.4%
- Successful Financing: China SXT Pharmaceuticals, Inc. announced the closing of a registered direct offering valued at approximately $10 million, selling 66,666,666 Class A ordinary shares at $0.15 each to a single investor, thereby strengthening its balance sheet and boosting investor confidence.
- Financial Guidance: TG Therapeutics reported preliminary U.S. net product revenue for its multiple sclerosis therapy BRIUMVI for Q4 and full-year 2025, with shares rising 6.99% to $29.82, showcasing the company's growth potential.
- FDA Review Progress: Argenx SE's supplemental Biologics License Application for VYVGART, aimed at treating adults with acetylcholine receptor antibody seronegative generalized myasthenia gravis, has been accepted for priority review by the FDA, with a target action date of May 10, 2026, indicating potential for expanded indications.
- Market Trends: Cosmos Health Inc. saw its stock rise 6.09% to $0.4961 despite no specific news, reflecting speculative interest and momentum trading in the micro-cap healthcare sector.
Cerus (CERS) Q4 Product Revenue Expected at $57.8M, 14% YoY Growth
- Revenue Growth: Cerus anticipates Q4 product revenue to reach $57.8 million, reflecting a 14% year-over-year increase, indicating strong momentum in its blood safety products, particularly the IFC segment.
- IFC Performance: The INTERCEPT Fibrinogen Complex (IFC) is expected to contribute $4.2 million in Q4, showcasing a year-over-year growth of approximately 40%, which underscores the increasing market demand for this product and strengthens Cerus's competitive position.
- Full-Year Outlook: For FY 2025, Cerus raises its product revenue guidance to a range of $202 million to $204 million, representing a 14% increase year-over-year, with IFC expected to account for $16.7 million, reflecting an impressive 80% growth, demonstrating the company's confidence in future performance.
- 2026 Revenue Guidance: The company projects FY 2026 product revenue between $224 million and $228 million, indicating a year-over-year growth of 9%-11%, with expected IFC revenue of $20 million to $22 million, translating to a 20%-30% increase, laying a solid foundation for sustained growth ahead.
Cerus Reports 14% Increase in 2025 Product Revenue to $206.1 Million
- Significant Revenue Growth: Cerus reported a product revenue of $206.1 million for 2025, reflecting a 14% increase from 2024, indicating sustained demand in the global blood safety market and enhancing its market position.
- Expanded Patient Access: By facilitating approximately 3 million INTERCEPT treated blood component doses across 40 countries, Cerus demonstrates the widespread application of its products globally, further solidifying its leadership in the industry.
- Positive Future Outlook: Cerus anticipates multiple milestones in 2026, including continued expansion of its commercial reach and advancement of its product development pipeline, which will help improve the company's financial performance and competitive edge.
- Enhanced Financial Transparency: Cerus plans to release complete financial results for 2025 in early March 2026, boosting investor confidence in the company's financial health and increasing market interest in its stock.
Biotech Stocks Rise in After-Hours Trading Driven by Data Expectations and Momentum Buying
Biotech Market Gains: After-hours trading on Wednesday saw significant gains in small-cap and micro-cap biotech stocks, driven by a mix of upcoming clinical milestones and a general positive sentiment in the market following the Fed's rate cut.
Agape ATP Corp. Surge: Agape ATP Corp. experienced a notable 29.41% increase in after-hours trading, attributed to a broader risk-on reaction in micro-cap stocks, despite no specific news from the company.
Corbus Pharmaceuticals Update: Corbus Pharmaceuticals saw a 12.76% rise ahead of a key clinical update regarding its Phase 1a study of CRB-913, with anticipation around the upcoming data likely fueling investor interest.
Other Notable Movers: Companies like Anebulo Pharmaceuticals, Cue Biopharma, and Curis also reported gains in after-hours trading, reflecting a broader recovery in biotech sentiment, while Cerus Corporation continued its upward trend following a new purchasing agreement.
Cerus Corporation Unveils Abstracts and Hosts Industry Workshop on IFC at the 2025 AABB Annual Meeting
Cerus Corporation Workshop Announcement: Cerus Corporation will host a workshop on the benefits of INTERCEPT Fibrinogen Complex at the 2025 AABB Annual Meeting in San Diego, emphasizing their commitment to innovations in transfusion medicine.
Abstract Presentations: Eighteen Cerus-related abstracts will be presented at the AABB meeting, showcasing the impact of their technologies on blood safety and availability.
Workshop Details: The workshop, scheduled for October 27, 2025, will feature speakers from the University of California, San Diego, and OneBlood, focusing on blood center perspectives regarding INTERCEPT Fibrinogen Complex.
Company Overview: Cerus Corporation is dedicated to enhancing blood safety through its INTERCEPT Blood System, which is globally available and FDA-approved for pathogen reduction in blood components.
